Check out our most popular compounded medications! Get Started
Bayview Pharmacy's Estriol/Estradiol/Estrone [80%-10%-10%] 0.625-2.5 mg Slow Release Capsules are a specialized compounded medication. Formulated with Methocel E4M, a controlled-release polymer, these capsules are designed to gradually release the active ingredients over an extended period. This slow-release mechanism offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance. The medication is primarily used to manage menopausal symptoms, osteoporosis, uterine prolapse, vaginal atrophy, and dyspareunia.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
This compounded formulation of Estriol/Estradiol/Estrone [80%-10%-10%] 0.625-2.5 mg Slow Release Capsules is designed to provide a controlled and prolonged release of hormones, offering sustained therapeutic effects. The formulation is encapsulated in Methocel E4M, a type of controlled-release polymer, which ensures the gradual release of the active ingredients over an extended period of time. This reduces the dosing frequency and improves patient compliance, particularly for those requiring a controlled release profile.
The formulation contains a combination of estriol, estradiol, and estrone in a ratio of 80%-10%-10%. Each of these hormones plays a crucial role in managing various disease states. Estriol, a weaker form of estrogen, helps to mitigate the risk of breast cancer. Estradiol, a stronger form of estrogen, aids in reducing the risk of cardiovascular disease. Estrone, another form of estrogen, helps to lower the risk of endometrial cancer.
The slow release of these hormones ensures a consistent level in the body, reducing the risk of side effects associated with hormone replacement therapy. This formulation is particularly beneficial for patients experiencing menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. It also aids in reducing the risk of postmenopausal osteoporosis and other conditions associated with hormone imbalances.
For healthcare providers, this formulation serves as a valuable tool in the treatment of menopausal symptoms, postmenopausal osteoporosis, and hormone replacement therapy. The combination of estriol, estradiol, and estrone in this formulation, along with the slow release capsule, ensures a more consistent level of hormones in the body, thereby reducing the risk of side effects associated with hormone replacement therapy.
If you have any questions about this formulation, please do not hesitate to contact us at Bayview Pharmacy. Our team of compounding pharmacists is here to assist you with any queries you may have.
This compounded formulation of Estriol/Estradiol/Estrone [80%-10%-10%] 0.625-2.5 mg Slow Release Capsules is designed to provide a controlled and prolonged release of the active ingredients. The formulation is encapsulated with Methocel E4M, a controlled-release polymer, which allows for a gradual release of the medication over an extended period of time. This slow release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance.
The formulation is primarily used for the treatment of menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. It may also be prescribed for the treatment of osteoporosis and to reduce the risk of developing endometrial hyperplasia in postmenopausal women. Additionally, it can be used to treat hypoestrogenism, a condition characterized by insufficient estrogen production in the body.
However, this formulation is not recommended for use in pregnant or breastfeeding women due to potential harm to the fetus or infant. It is also contraindicated in women with a history of breast cancer, endometrial cancer, or other estrogen-dependent cancers, as well as in women with a history of stroke, blood clots, or liver disease.
Patients should be aware of potential side effects, which may include nausea, headache, breast tenderness, and fluid retention. There is also an increased risk of developing endometrial hyperplasia, breast cancer, and other estrogen-dependent cancers. Furthermore, this formulation may interact with other medications, such as anticoagulants, insulin, and certain antibiotics.
Prescribers should exercise caution when prescribing this formulation to patients with a history of stroke, blood clots, or liver disease, as well as to those with a history of breast cancer, endometrial cancer, or other estrogen-dependent cancers. It is also important to consider potential interactions with other medications, such as anticoagulants, insulin, and certain antibiotics.
If you have any questions about this formulation or its potential interactions, please do not hesitate to reach out for further information.
This compounded formulation combines estriol, estradiol, and estrone in a ratio of 80%-10%-10%, encapsulated in slow release capsules containing 0.625-2.5 mg of each hormone. It is designed to treat a variety of conditions, including menopausal symptoms, osteoporosis, and as part of hormone replacement therapy.
The estriol component is primarily used to alleviate menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. It also plays a role in reducing the risk of osteoporosis and in maintaining bone density. Estradiol, like estriol, is used to treat menopausal symptoms and to help maintain bone density, thereby reducing the risk of osteoporosis. Estrone, on the other hand, is used not only to treat menopausal symptoms and maintain bone density but also to reduce the risk of breast cancer.
The unique feature of this formulation is the slow release capsules. These capsules are formulated with Methocel E4M, a type of controlled-release polymer. This design allows for a gradual and sustained release of the hormones into the body, providing a more consistent level of hormones over time. This controlled release helps to mitigate the risk of side effects associated with sudden changes in hormone levels.
While this formulation is generally well tolerated, potential side effects may occur. These can include nausea, headache, breast tenderness, and weight gain. It is crucial to discuss any potential side effects with your healthcare provider before starting this medication.
If you have any questions about this formulation or its mechanism of action, please do not hesitate to reach out. We are here to provide the necessary information and support.
This Estriol/Estradiol/Estrone [80%-10%-10%] 0.625-2.5 mg Slow Release Capsule formulation is designed to provide a controlled and prolonged release of the active ingredients. The formulation is encapsulated with Methocel E4M, a controlled-release polymer, which allows for the gradual release of the medication over an extended period. This slow release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled release profile.
The formulation is used to treat a variety of conditions, including endometriosis, premenstrual syndrome, polycystic ovarian syndrome, and postmenopausal bleeding. It may also be used to reduce the risk of developing certain types of cancer, such as breast and ovarian cancer. Additionally, this formulation may be used to reduce the risk of developing cardiovascular disease, improve bone density, reduce the risk of fractures, and potentially reduce the risk of developing dementia and Alzheimer's disease. It may also be used to reduce the risk of developing depression and anxiety.
It is crucial to understand that this formulation should only be used under the supervision of a healthcare provider. The dosage and duration of treatment should be tailored to the individual patient's needs and should be based on the patient's medical history, current symptoms, and other factors. Patients should be monitored closely for any adverse effects, and the dosage should be adjusted accordingly.
If you have any questions about the use of this formulation, please do not hesitate to reach out. It is our goal to provide you with the most comprehensive and accurate information to ensure your health and well-being.
The capsules are composed of Estriol, Estradiol, and Estrone in the ratio of 80%-10%-10% respectively. The dosage ranges from 0.625 to 2.5 mg.
Methocel E4M is a type of controlled-release polymer. It is designed to release the encapsulated medication or active ingredient gradually over an extended period of time. This offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile.
Slow-release formulations offer several benefits. They provide sustained therapeutic effects, reduce the frequency of dosing, and improve patient compliance, especially for medications that require a controlled and prolonged release profile.
Due to the slow-release nature of these capsules, the frequency of dosing is reduced. However, the exact frequency will depend on your doctor's prescription and your specific health condition.
The therapeutic effects of these capsules are sustained over an extended period due to the slow-release formulation. The exact effects will depend on your specific health condition and the prescribed dosage.
Before starting any new medication, it is important to discuss your full medical history with your doctor. This includes any hormone-related health issues. Your doctor will be able to determine if this medication is suitable for you.
If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
As with any medication, there may be potential side effects. It is important to discuss these with your doctor before starting the medication. If you experience any adverse effects while taking the medication, contact your doctor immediately.
Before starting any new medication, it is important to discuss with your doctor all the medications you are currently taking. This includes prescription medications, over-the-counter drugs, and any supplements. Your doctor will be able to determine if there are any potential interactions.
Store these capsules in a cool, dry place away from light and heat. Keep out of reach of children. Do not store in a bathroom or kitchen, as the humidity can affect the medication.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
